Healthcare >> CEO Interviews >> May 27, 2003
DANIEL GLASSMAN is Chairman of the Board, President and Chief Executive
Officer of Bradley Pharmaceuticals, Inc., which he founded in 1985. Mr.
Glassman was the key force that took the company public as a NASDAQ
traded corporation in November 1991 and drove the transition to the New
York Stock Exchange on May 13, 2003. Mr. Glassman also is Chairman of
the Board and Chief Executive Officer of Doak Dermatologics, Bradley
Pharmaceuticals Ltd., each a subsidiary of Bradley Pharmaceuticals,
Inc. Mr. Glassman has 32 years experience in pharmaceutical management
and healthcare communications. He is actively involved in the
development of medical education programs for numerous pharmaceutical
and medical professional associations. Mr. Glassman is an associate
member of the American Academy of Dermatology as well as a lecturer,
publisher and author. He has been named the Ernst & Young LLP
Entrepreneur of the Year (1995) in the New Jersey Life Sciences
division. Mr. Glassman pursued his undergraduate degree at Columbia
University, where he served as Class President from 1960-1962 and
Student Council President from 1962-1963. He received his BS in
Pharmacy, and went on to achieve an MBA from New York University. Mr.
Glassman serves as a member of the University Advisory Committee, Long
Island University Health Sciences and has authored a chapter entitled
'The History of the FDA Communications Regulations' in a soon-to-be-
published book. Profile
Pharmaceuticals?
Mr. Glassman: Bradley Pharmaceuticals was founded in 1985 as a
specialty pharmaceutical company that markets to niche
